Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1823911 Monotherapy and Combination Therapy in Advanced Solid Tumors with KRAS G12C Mutation
NCT04973163Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2021
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of BI 1823911 in solid tumor (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicities at 28 days and Objective Response at 39 months. Started Sep 2021; status: active, not recruiting.
02
Drugs
BI 1823911
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04973163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973163.